Clinical data | |
---|---|
Trade names | Vistide |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | complete |
Protein binding | <6% |
Elimination half-life | 2.6 hours (active metabolites: 15–65 hours) |
Excretion | renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid.[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.166.433 |
Chemical and physical data | |
Formula | C8H14N3O6P |
Molar mass | 279.189 g·mol−1 |
3D model (JSmol) | |
Specific rotation | -97.3 |
Melting point | 260 °C (500 °F) |
| |
| |
(verify) |
Cidofovir, brand name Vistide, is a topical or injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS.[4][5]
Cidofovir was approved for medical use in 1996.[6]
MSR
was invoked but never defined (see the help page).TGA
was invoked but never defined (see the help page).